Downloads: 96 | Views: 146

Review Papers | Psychiatry | India | Volume 9 Issue 4, April 2020

FETZIMA (Levomilnacipran-ER Capsules) - For the Treatment of Major Depressive Disorder: A Comprehensive Review

Dr. V. Sai Rathna | Dr. R. Bhanu Prasad | Dr. C. Nithish

Abstract: The Present Review paper emphasis on the drug named Levomilnacipran-ER capsules indicated for Major Depressive disorder, as Depression is a chronic mental disorder that causes changes in mood, thoughts, behaviour and Physical health. It is fortunated that by 2030, Depressive disorders would project as one of the top three causes of Global disease burden. Prevalence has been estimated to be within a range of 10-25% in females and 5-12% among males. It acts by increasing the serotonin and norepinephrine in Central Nervous system through inhibition of reuptake of serotonin and norepinephrine transporters as its exhibits 10 times greater selectivity when compared with other drugs in SNRI's. It has a bioavailability of around 92% ans Maximum Plasma Concentration is attained within 6-8 hours and 58% of unchanged compound was excreted in urine, manufactured in market with dosage of 20mg, 40mg, 80mg, 120mg. Suicidal thoughts, Serotonin syndrome, Discontinuation Syndrome are some of the major adverse effects. A wide variety of research has been conducted in yester years. Administration of the Levomilnacipran should be performed under the keen supervision as per physician's advice.

Keywords: Levomilnacipran, Major Depressive Disorder, Psychomotor activity, Plaasma Concentration, Bioavailability, Suicidal thoughts

Edition: Volume 9 Issue 4, April 2020,

Pages: 793 - 796